Inflammation-induced Expression of Sialyl Lewis X-containing Glycan Structures on α1-Acid Glycoprotein (Orosomucoid) in Human Sera

By Truus W. De Graaf, Marleen E. Van der Stelt, Mariette G. Anbergen, and Willem van Dijk

From the Department of Medical Chemistry, Faculty of Medicine, Vrije Universiteit, 1081 BT Amsterdam, The Netherlands

Summary

The glycosylation of the acute phase glycoprotein α1-acid glycoprotein (AGP) in human sera is subject to marked changes during acute inflammation as a result of the cytokine-induced hepatic acute phase reaction. The changes described thus far comprise alterations in the type of branching of the carbohydrate structures as revealed by increased reactivity of AGP with concanavalin A. We now report on acute inflammation-induced increases in α1→3-fucosylated AGP molecules, as detected by the reactivity of AGP towards the fucose-binding Aleuria aurantia lectin (AAL) in crossed affino-immunoelectrophoresis of human sera. Laparotomy of women, for the removal of benign tumors of the uterus, was used as a model for the development of the hepatic acute phase response. Huge increases were detected in the amounts of strongly AAL-reactive fractions of AGP, presumably containing three or more fucosylated N-acetylactosamine units. At least part of these Lewis X-type glycans (Galβ1→3[Fucα1→3]GlcNAc-R) appeared to be substituted also with an α2→3-linked sialic acid residue. This was revealed by the laparotomy-induced abundant staining of AGP with an antisialyl Lewis X monoclonal antibody (CSLEX-1) on blots of sodium dodecyl sulfate-polyacrylamide gels containing AGP isolated from the sera of a patient at various days after operation. It is concluded that acute inflammation induces a strong increase in sialyl Lewis X-substituted AGP molecules that persists at a high level throughout the inflammatory period. We postulate that these changes represent a physiological feedback response on the interaction between leukocytes and inflamed endothelium, which is mediated via sialylated Lewis X structures and the selectin endothelial-leukocyte adhesion molecule 1.

Characteristic changes in the glycosylation of α1-acid glycoprotein (AGP) and other acute phase glycoproteins occur during the acute phase of inflammation with respect to the degree of branching of the N-linked glycans on the molecules (1–6). Cytokines, like IL-1, IL-6, and TNF, involved in the induction of the inflammatory reaction have been shown to be responsible for these changes by affecting the glycosylation process in the liver (5, 7–10). The function of the changes in glycosylation is not known, although effects on immunomodulative properties of AGP and α1-protease inhibitor (PI) have been described (11–14). In liver cirrhosis and in cancer sera the occurrence has been described of AGP and other serum glycoproteins expressing fucosylated and sialylated glycans of the type sialyl Lewis X (SLeX; NeuAcα2→3Galβ1→4[Fucα1→3]GlcNAc-R) (15–18). In normal serum, however, only a low expression of SLeX on serum glycoproteins has been reported (15, 17, 18). The Lewis X structure in its sialylated form is of special interest because this structure, when present on leukocytes, is the ligand for the cell adhesion molecules E-Selectin (the endothelial-leukocyte adhesion molecule [ELAM]-1) and P-Selectin (GMP140/PADGEM/CD62), involved in the inflammation-dependent adhesion of neutrophils, monocytes, or resting T cells to vascular endothelium or platelets (19–23). E-Selectin and P-Selectin are normally not expressed on the cell surface of the cells, but can be induced rapidly upon stimulation with inflammatory mediators. Walz et al. (19) have described that AGP has an affinity for E-Selectin and that this affinity can be substantially increased by in vitro fucosylation of AGP increasing most probably the expression of SLeX on the
Materials and Methods

Sources of Sera. Control sera were obtained from apparently healthy individuals. Serum samples of women, subjected to laparotomy either for the removal of benign tumor(s) of the uterus or for primary Caesarean section, were taken 24 h before operation and at several days after operation until they were released from the hospital. Serum samples of previously healthy burn patients were taken within hours of the injury and at regular intervals within the following 2 mo, as detailed elsewhere (5).

Isolation of Aleuria aurantia Lectin (AAL). Fruiting bodies of Aleuria aurantia were collected locally and stored frozen at ~80°C in 200-g portions. Fruiting bodies (200 g) were homogenized in 1.5 vol (vol/wt) 10 mM phosphate buffer (pH 7.2), 0.14 M NaCl, 0.02% NaN₃ (PBS) using a Polytron homogenizer (Kinematica GmbH, Kriens/Luzern, Switzerland). The lectin was extracted by stirring the homogenate for 4 h at 4°C followed by centrifugation for 30 min at 14,000 rpm (4°C; 6X300 rotor, MSE 21), and was subsequently precipitated by ammonium sulphate (80% saturation). The precipitate was resuspended in 150 ml PBS, followed by dialysis against PBS for 24 h with three changes of the buffer. Residual insoluble materials were removed from the retentate by centrifugation (40 min; 40,000 rpm at 4°C; 8X50 rotor, MSE 65). AAL was isolated from the crude preparation by affinity chromatography according to Debray and Montreuil (24) using an L-fucose-agarose column (1.8 x 12 cm; F7379; Sigma Chemical Co., St. Louis, MO) at a flow rate of 10 ml/h. The column was washed with PBS until the absorption at A₂₅₀ nm of the effluent was negligible. Specific elution of the lectin was performed with two-column volumes of PBS, 0.15 M α-L-fucose (Sigma Chemical Co.). The eluate was dialyzed against 10 times diluted PBS for 4 d with six changes of the buffer. The hemagglutination titer of AAL was determined after immobilization of the isolated lectin on activated CH-Sepharose 4B (4 mg/ml) (Pharmacia LKB, Uppsala, Sweden). Chromatography on AAL-Sepharose 4B was performed using a 1.3-ml column (0.3 x 18 cm; 4 ml/h; 0.2-ml fractions; 20°C) and PBS, 0.02% NaN₃ as starting buffer. Radiactively labeled standard glycopeptides or oligosaccharides were applied in 0.1 ml of starting buffer. Nonbound and weakly retarded compounds were eluted with five-column volumes of starting buffer. Retarded or bound glycan were eluted with 10 mM L-fucose in starting buffer. The radioactivity in each fraction was determined by liquid scintillation. The AAL-Sepharose column was regenerated with 10-column volumes of starting buffer.

All standard structures used were characterized previously by ¹H-NMR or capillary gas chromatography/mass fragmentography. [2-H]Man-labeled (Man₁-GlcNAcOH [Man₁→2Man₀→2Man₁→3] [Man₁→3] [Man₆→2Man₁→6] [Man₁→6] →Man₁→4GlcNAcOH) was a kind gift from Dr. R. Geyer (Biochemisches Institut an der Universität Giessen, Giessen, Germany) (25). AAL was collected locally and stored frozen at ~80°C in 200-g portions. Fruiting bodies (200 g) were homogenized in 1.5 vol (vol/wt) 10 mM phosphate buffer (pH 7.2), 0.14 M NaCl, 0.02% NaN₃ (PBS) using a Polytron homogenizer (Kinematica GmbH, Kriens/Luzern, Switzerland). The lectin was extracted by stirring the homogenate for 4 h at 4°C followed by centrifugation for 30 min at 14,000 rpm (4°C; 6X300 rotor, MSE 21), and was subsequently precipitated by ammonium sulphate (80% saturation). The precipitate was resuspended in 150 ml PBS, followed by dialysis against PBS for 24 h with three changes of the buffer. Residual insoluble materials were removed from the retentate by centrifugation (40 min; 40,000 rpm at 4°C; 8X50 rotor, MSE 65). AAL was isolated from the crude preparation by affinity chromatography according to Debray and Montreuil (24) using an L-fucose-agarose column (1.8 x 12 cm; F7379; Sigma Chemical Co., St. Louis, MO) at a flow rate of 10 ml/h. The column was washed with PBS until the absorption at A₂₅₀ nm of the effluent was negligible. Specific elution of the lectin was performed with two-column volumes of PBS, 0.15 M α-L-fucose (Sigma Chemical Co.). The eluate was dialyzed against 10 times diluted PBS for 4 d with six changes of the buffer. The hemagglutination titer of AAL was determined after immobilization of the isolated lectin on activated CH-Sepharose 4B (4 mg/ml) (Pharmacia LKB, Uppsala, Sweden). Chromatography on AAL-Sepharose 4B was performed using a 1.3-ml column (0.3 x 18 cm; 4 ml/h; 0.2-ml fractions; 20°C) and PBS, 0.02% NaN₃ as starting buffer. Radiactively labeled standard glycopeptides or oligosaccharides were applied in 0.1 ml of starting buffer. Nonbound and weakly retarded compounds were eluted with five-column volumes of starting buffer. Retarded or bound glycan were eluted with 10 mM L-fucose in starting buffer. The radioactivity in each fraction was determined by liquid scintillation. The AAL-Sepharose column was regenerated with 10-column volumes of starting buffer.

CAIE. CAIE with Con A or Pisum sativum agglutinin (PSA) as affinity component in the first-dimension gel was performed according to Bøg-Hansen (27), as previously described (5), using 2 mg Con A (Type V; Sigma Chemical Co.) or 5 mg PSA (crude preparation; EY Labs, San Mateo, CA) gel. The first-dimension gel for CAIE with AAL was prepared from a mixture of 300 μl AAL preparation (hemagglutination titer 512), 75 μl five times concentrated electrophoresis buffer, and 625 μl 1.6% agarose (Standard Low m, Agarose; Bio-Rad Laboratories, Richmond, CA)/ml gel. The first-dimension gel for CAIE with AAL was prepared from a mixture of 300 μl AAL preparation (hemagglutination titer 512), 75 μl five times concentrated electrophoresis buffer, and 625 μl 1.6% agarose (Standard Low m, Agarose; Bio-Rad Laboratories, Richmond, CA)/ml gel. The first-dimension gel for CAIE with AAL was prepared from a mixture of 300 μl AAL preparation (hemagglutination titer 512), 75 μl five times concentrated electrophoresis buffer, and 625 μl 1.6% agarose (Standard Low m, Agarose; Bio-Rad Laboratories, Richmond, CA)/ml gel. The first-dimension gel for CAIE with AAL was prepared from a mixture of 300 μl AAL preparation (hemagglutination titer 512), 75 μl five times concentrated electrophoresis buffer, and 625 μl 1.6% agarose (Standard Low m, Agarose; Bio-Rad Laboratories, Richmond, CA)/ml gel.

Characterization of the Binding Specificity of AAL. The binding specificity of AAL was determined after immobilization of the isolated lectin on activated CH-Sepharose 4B (4 mg/ml) (Pharmacia LKB, Uppsala, Sweden). Chromatography on AAL-Sepharose 4B was performed using a 1.3-ml column (0.3 x 18 cm; 4 ml/h; 0.2-ml fractions; 20°C) and PBS, 0.02% NaN₃ as starting buffer. Radiactively labeled standard glycopeptides or oligosaccharides were applied in 0.1 ml of starting buffer. Nonbound and weakly retarded compounds were eluted with five-column volumes of starting buffer. Retarded or bound glycan were eluted with 10 mM L-fucose in starting buffer. The radioactivity in each fraction was determined by liquid scintillation. The AAL-Sepharose column was regenerated with 10-column volumes of starting buffer.

The binding specificity of AAL was determined after immobilization of the isolated lectin on activated CH-Sepharose 4B (4 mg/ml) (Pharmacia LKB, Uppsala, Sweden). Chromatography on AAL-Sepharose 4B was performed using a 1.3-ml column (0.3 x 18 cm; 4 ml/h; 0.2-ml fractions; 20°C) and PBS, 0.02% NaN₃ as starting buffer. Radiactively labeled standard glycopeptides or oligosaccharides were applied in 0.1 ml of starting buffer. Nonbound and weakly retarded compounds were eluted with five-column volumes of starting buffer. Retarded or bound glycan were eluted with 10 mM L-fucose in starting buffer. The radioactivity in each fraction was determined by liquid scintillation. The AAL-Sepharose column was regenerated with 10-column volumes of starting buffer.
brilliant blue R 250 (5). The area of each AGP or PI form under the precipitation line was measured using planimetry and the reactivity coefficient (RC) was calculated for each pattern. The RC was defined as the ratio between the sum of the areas of lectin-reactive forms and the area of the nonreactive form. The total amounts of AGP and PI as present in the various samples were determined by circular immunodiffusion (28).

Partial Purification of AGP from Serum. Isolation of AGP from serum was performed by immunoaffinity chromatography over an anti-AGP-Sepharose 4B column (prepared from CH-Sepharose 4B [Pharmacia-LKB] and rabbit anti-human AGP IgG according to the instructions of the supplier). 0.5 ml of serum was applied to the anti-AGP-Sepharose 4B column (2.4 × 0.8 cm; 5 ml/h). The Sepharose column was subsequently washed with PBS until the absorption at A280 nm of the effluent was negligible. Specific elution of the bound AGP was performed with 0.05 M diethyamine (pH 11.5), 0.15 M NaCl, 0.02% NaN3 under immediate neutralization of the eluted fractions. AGP-containing fractions (as detected by rocket immunoelectrophoresis) were pooled, dialyzed extensively against 0.1 M ammonium bicarbonate (pH 8.0), lyophilized, and stored at -20 °C. The amount of AGP in each preparation was determined by radial immunodiffusion (28).

Isolation of Various Con A- or AAL-reactive Fractions of AGP. Various lectin-reactive fractions of sera were obtained by preparative CIE (6, 7). In short, the method involved the electrophoretic separation of the various lectin-reactive AGP forms in a Con A- or AAL-containing agarose gel in which 75 μl of serum was applied in various gels. Gels containing the nonretarded and the lectin-retarded forms were cut out perpendicular to the electrophoresis direction, after determination of the positions of the various forms in small control lanes by immunoelectrophoresis in the second dimension using rabbit anti-human AGP IgG. The glycoprotein forms were recovered from the lectin-containing gels by electrophoresis into a second-dimension agarose gel without additions. A small intermediate gel containing the appropriate sugar(s) was used to dissociate lectin-glycoprotein complexes. The various lectin-reactive forms of AGP were collected from the second-dimension gels by electroelution (422 Electro-Eluter; Bio-Rad Laboratories).

SDS-PAGE Blotting, and Immunoassay of AGP. 10% SDS-PAGE was performed according to Laemmli (30) using the Mini-Protein II dual slab gel apparatus (Bio-Rad Laboratories). Gels were loaded with equal amounts of AGP as present in patient sera or in partially purified preparations of AGP from the sera of one of the patients. AGP isolated from pooled normal human serum (4) was used as a standard. Protein bands were detected by staining of the gels with coomassie brilliant blue R250. Proteins were blotted onto nitrocellulose by electrophoretic transfer using the Mini Trans-Blot Cell (Bio-Rad Laboratories). AGP was detected on the blots using rabbit anti-human AGP IgG and peroxidase-conjugated goat anti-rabbit IgG (Nordic Immunology, London, UK). SLeX determinants on AGP were detected by incubating AGP-containing nitrocellulose strips with mouse monoclonal anti-SLeX IgM (CSLEX-1, 20 μg/ml in 10 times diluted PBS; Tissue Typing Laboratory, Department of Surgery, UCLA School of Medicine, Los Angeles, CA) (31), followed by alkaline phosphatase-conjugated goat anti-mouse IgM (1:250; vol/vol; Zymed Laboratories, San Francisco, CA) for detection. The specificity of the binding of the CSLEX-1 antibody was checked by desialylation of AGP preparations with neuraminidase (Vibrio cholerae; Boehringer, Mannheim, Germany) (0.1 U/ml, 2 h, 37 °C) before SDS-PAGE.

Results

Control of the Specificity of Binding of AAL. The AAL preparations exhibited the same binding characteristics for α1→3- and α1→6-linked complex type glycans as reported by Debray and Montreuil (24) when the lectin was immobilized on CH-Sepharose 4B (AAL-Sepharose; Table I). N-linked complex-type glycopeptides substituted with an α1→3-linked Fuc residue (the GP4MF isomers) were retarded by 0.5 (GP4MF3) to one-column volume of PBS (GP4MF1 and -2). The Fucα1→6-substituted glycopeptide MS was strongly retarded on the AAL-Sepharose column since it was eluted with 5–10-column volumes of PBS or (specifically) with one-column volume of PBS containing 0.05 M i-Fuc. Non-fucosylated bi-, tri-, and tetraantennary complex-type glycans as well as the oligomannose saccharide (Man)5GlcNAcOH were neither bound nor retarded.

Reactivity of AGP in Control Human Sera with the Fucose-specific Lectins AAL and PSA. AGP present in pooled normal human sera was fractionated in a nonreactive and four reactive fractions upon CAIE with AAL as affino component (Fig. 1). All fractions were recovered on the same positions upon reanalysis by CAIE with AAL, after fractionation of serum in different AAL-reactive fractions by preparative CAIE (not shown). Analyses of 16 different sera of apparently healthy volunteers revealed that 40 ± 13% of AGP did not interact at all with AAL (A0), and 14 ± 2% (A1), 16 ± 3% (A2), 13 ± 5% (A3), and 17 ± 8% (A4) of AGP were retarded by AAL to different extents. No retardation was detectable for AGP when sera were subjected to CAIE with the Fucα1→6-specific lectin PSA as affino component (not shown).

Acute Phase-induced Increases in the Reactivity of AGP with AAL. Laparotomy of women for the removal of benign tumors of the uterus was used as a model of the acute phase response in serum. The development of the acute phase reaction after laparotomy is illustrated by the changes in the total amount and in the Con A reactivity of AGP (Fig. 2 and Table 2). All three patients displayed a strong increase in the AAL reactivity of AGP after the onset of acute inflammation. The increase in AAL reactivity especially regarded forms A3 and A4 of AGP, as is illustrated in Fig. 2. The highest increases in AAL reactivity were noted at the end of the period studied. The changes in reactivity with Con A and AAL occurred independently from each other and from the changes in the total amount of AGP.

Like in control sera (see above), no retardation of AGP was detectable in the sera of the various patients when analyzed by CAIE with the Fucα1→6-specific lectin PSA. This indicates that the increased AAL reactivity of AGP did not concern the de novo expression of α1→6-linked Fuc residues, at least with regard to biantennary glycans (32, 33). Since, in addition, the common type of fucosylation of AGP is in an α1→3 linkage (4, 33, 34), the observed change in AAL reactivity was most likely evoked by an increased substitution of the glycans with α1→3-linked Fuc residues. PSA did react with PI revealing the presence of α1→6-linked Fuc residues. However, no acute phase-induced changes could be detected in the reactivity of this Fucα1→6-substituted acute...
Table 1. Characterization of Carbohydrate Binding Specificity of AAL-Sepharose

| Glycopeptide or oligosaccharide | Schematic structure | Elution behavior |
|----------------------------------|---------------------|-----------------|
| GP2                              |                     | Not retarded    |
| MS                               |                     | Eluted with 0.05 M α-L-Fuc in PBS |
| GP3                              |                     | Not retarded    |
| GP4                              |                     | Not retarded    |
| GP4MF1                           |                     | Retarded by one-column volume PBS |
| GP4MF2                           |                     | Retarded by one-column volume PBS |
| GP4MF3                           |                     | Retarded by 0.5-column volume PBS |
| (Man)₃GlcNAcOH                   |                     | Not retarded    |

Not retarded glycans were eluted in the void volume with the washing buffer PBS. The structures are depicted in a schematic form, with numbers indicating the positions of substitution at the branching points. See Materials and Methods for the definition of the standard structures and for details of the chromatographic procedure used.

* Fucose residues.

Acute Phase-induced Increase in the Expression of SLeX Antigens on AGP. To establish whether the acute phase-induced change in AAL reactivity of AGP involved an increased occurrence of fucosylated and sialylated N-acetyllactosamine units of the type NeuAcα2→3Galβ1→4(Fucα1→3)GlcNAc-R (SLeX), the expression of this type of antigen on AGP was studied during the development of the acute phase using anti-SLeX monoclonal IgM. The presence of SLeX antigens on AGP could not be unequivocally established on nitrocellulose blots of SDS-PAGE gels of total sera, because of both comigrating other serum glycoproteins and the low sensitivity of the method. It was decided, therefore, to perform the analyses on immunoaffinity-purified AGP. For obvious reasons this effort was performed only for one set of sera (patient 1 of Table 2). SDS-PAGE of equal amounts of purified AGP fractions revealed broad protein bands at 43 kD (4) that comigrated with standard AGP and reacted with anti-human AGP antibodies (Fig. 3 A). A weak positive staining with anti-SLeX was observed for AGP isolated from serum before operation (Fig. 3 B). Strongly enhanced staining was observed
Figure 1. Reactivity of AGP in control human serum with AAL. The reactivity of AGP with AAL was determined by CAIE as described in Materials and Methods using 1 μl of pooled human sera and rabbit anti-human AGP IgG for detection. Only the second-dimension gel is shown; the application site in the first-dimension gel coincides with the right hand side of the figure. (A0) AGP fraction nonreactive with AAL; (A1–A4) reactive fractions with AAL in increasing order of reactivity.

Table 2. Effect of Laparotomy-induced Acute Inflammation on the Reactivity of AGP with AAL and Con A

| Patient 1 | Patient 2 | Patient 3 |
|-----------|-----------|-----------|
|           | AGP       | Con A     | AAL       | AGP       | Con A     | AAL       | AGP       | Con A     | AAL       |
| Day       | mg/ml     |           | mg/ml     |           | mg/ml     |           | mg/ml     |           | mg/ml     |
| -1        | 1.6       | 1.9       | 2.1       | 1.4       | 1.4       | 0.7       | 2.1       | 1.1       | 1.6       |
| +1        | 1.8       | 3.0       | 2.5       | 1.4       | 1.8       | 0.9       | 2.0       | 2.0       | 4.1       |
| +2        | 1.9       | 2.9       | 3.7       | -         | -         | -         | -         | -         | -         |
| +4        | 2.1       | 2.2       | 4.5       | 2.4       | 2.0       | 1.8       | -         | -         | -         |
| +5        | -         | -         | -         | -         | -         | -         | 1.7       | 1.4       | 6.5       |

The sera of women subjected to laparotomy for the removal of benign tumors of the uterus were analyzed before and at various days after operation for acute phase-induced changes in concentration (Mancini) and in lectin reactivity of AGP (CAIE). RC (reactivity coefficient), ratio of the sum of the lectin-retarded fractions over the nonretarded fraction of AGP. See Materials and Methods for details.
Acute-phase induced changes in concentration (Mancini) and in AAL reactivity of AGP (CAIE) were analyzed in sera of patients suffering from severe burns (Burns) or patients subjected to laparotomy for primary Caesarean section (PS) at various days during hospitalization. RC (reactivity coefficient), ratio of the sum of the lectin-retarded fractions over the non-retarded fraction of AGP. See Materials and Methods for details.

* Part of the values for the concentration of AGP in the sera of burn patients were published earlier (5).

**Figure 4.** AAL reactivity of AGP at various days after injury by burning. Sera were obtained at the first day (a), and 3 (b) and 30 d (c) after the injury by burning (burn patient 1 in Table 3). 2.5 (a) or 1 μl of serum (b and c) was analyzed by CAIE for the reactivity of AGP with AAL. See Fig. 2 for further explanation and Materials and Methods for details.

| Day after injury | Patient 1 | Patient 2 | Patient 3 |
|-----------------|-----------|-----------|-----------|
| Source of sera  | AGP AAL   | AGP AAL   | AGP AAL   |
| Burns* 1        | 0.8 2.7   | 0.8 3.0   | 1.8 2.3   |
| Burns 3         | 2.1 3.4   | - 4.3     | - 5.4     |
| Burns 4         | - - 3.8   | - 7.3     | - 9.2     |
| Burns 16        | - - 7.3   | - 7.3     | - 9.2     |
| Burns 19        | - - 4.6   | - 4.6     | - 7.3     |
| Burns 30        | 4.5 5.1   | - 5.1     | - 7.3     |
| PS -1           | 1.3 1.0   | 1.0 0.2   | 1.0 0.3   |
| PS +1           | 1.3 1.1   | 1.0 0.3   | 1.0 0.3   |
| PS +7           | 2.0 2.6   | 1.7 1.9   | 1.7 1.9   |

**Acute Phase-induced Expression of Sialyl Lewis X on α1-Acid Glycoprotein**

- **Figure 3.** Inflammation-induced increase in the expression of SLeX antigens on AGP. Immunoaffinity-purified preparations of AGP from the four sera of the laparotomy patient 1 (compare Fig. 2 and Table 2) were subjected to SDS-PAGE, followed by blotting and detection of AGP (a) or SLeX (b) with specific (monoclonal) antibodies. Only the part of the blots containing the AGP bands is reproduced. Care was taken that the same amount of AGP (8 μg) was applied in each lane of the various gels, as is demonstrated by the specific detection of AGP in a. (Lane 1) 1 d before operation; (lanes 2, 3, and 4), respectively, 1, 2, and 4 d after laparotomy. (Lane 0 in b) AGP isolated from pooled human serum. See Materials and Methods for further details.

- **Figure 5.** Simplified model of cytokine-induced feedback inhibition of E-Selectin-mediated cell adhesion during inflammation.
AGP in human sera. The absolute amount of fucosylated AGP molecules as well as the number of Fuc residues per molecule were enhanced under the various acute inflammatory conditions studied (Tables 2 and 3). The amount of AGP molecules expressing three or more Fuc residues was especially increased. This is concluded from the huge increases in the strongly retarded fractions A3 and A4 (see Figs. 2 and 4), under the assumption that the number of Fuc residues per fraction is the sole determinant for the extent of retardation by AAL (see references 27 and 35 for theoretical background of the method). The laparotomy-induced abundant staining of AGP with a SLeX-specific mAb (Fig. 3) demonstrates that a significant part of the fucosylated N-acetyllactosamine units of the glycans were substituted also with an α2→3-linked sialic acid residue. So, acute inflammation appears to induce a strong increase in the SLeX-substituted glycans per AGP molecule, which persists at a high level throughout the whole period studied. Increases in SLeX-bearing glycans on acute phase glycoproteins have thus far only been reported in chronic inflammation and in sera from patients with cancer (15–17).

Fucosylated glycans recognized by AAL might express α1→3-, α1→6-, and/or α1→2-linked glycans. The reactivities of the AGP molecules with AAL, however, only reflect the interaction with Fuc residues in an α1→3 linkage to type II N-acetyllactosamine units (Lewis X) of the asparagine-linked glycans for the following arguments. (a) Fuc residues on AGP molecules isolated from normal human sera have been shown to occur only in an α1→3 linkage to the GlcNAc residue of one of the N-acetyllactosamine branches of the glycans (4, 34, 36, 37). (b) The N-acetyllactosamine units of AGP are of the type II (Galβ1→4GlcNAc) under normal (4, 34, 36, 37), inflamed (16), and tumorigenic conditions (33). (c) No interaction could be established between AGP and PSA, a lectin specific for Fucα1→6-substituted biantennary glycans (see Results). This type of glycan was only reported to be expressed on AGP isolated from human metastatic livers (33). PSA did react with PI, another acute phase glycoprotein synthesized by the liver, being indicative for the presence of α1→6-linked Fuc residues on PI. This type of linkage most probably was responsible also for the reactivity of PI with AAL, since during acute inflammation no changes were found in the reactivity of PI with either PSA or AAL. This further suggests that the hepatic biosynthesis of α1→6-linked Fuc residues was not affected by the inflammatory conditions. (d) The lack of change in AAL reactivity of PI also makes it very unlikely that α1→2-linked Fuc residues were introduced on serum glycoproteins during the hepatic acute phase reaction. Such a type of abnormal fucosylation has only been suggested to occur during liver diseases on PI and other acute phase glycoproteins (38, 39).

According to literature, 30–50% of the bi-, tri-, and tetraantennary N-linked glycans of normal AGP contain one Fuc residue (34, 36, 37), and a minor part of the tetraantennary glycans contains two Fuc residues (36). At least part of the fucosylated glycans were not fully substituted with α2→3- or α2→6-linked sialic acid residues (37), resulting in a low expression of SLeX on normal AGP (15). Since five glycans are present on each AGP molecule, it should be expected that all molecules would contain at least one fucosylated glycan. In this study, however, ~40% of the AGP molecules present in normal human sera apparently were not fucosylated at all, since they did not react with AAL in CAE. This indicates that in normal AGP the fucosylated structures are not distributed at random over the various molecules.

In previous studies it was established that at least three molecular forms of AGP occur in normal sera that differ in the degree of branching of the glycans, and that can be distinguished by their reactivities with Con A (4, 6). Con A–reactive AGP, containing one or two biantennary glycans, is increased during acute inflammation (1–7). Our present experiments exclude that a direct relationship exists between the inflammation-induced increases in biantennary glycan content and the extent of fucosylation of AGP. First, the changes in Con A and AAL reactivity differ both in magnitude and in time. For example, the AAL reactivity in burn sera increased steadily over a period of 30 d (Fig. 4), whereas the Con A reactivity reached maximal values in the first 16 d after injury and rapidly returned to control values thereafter (5). Second, the AAL reactivities of isolated Con A–reactive and nonreactive fractions of AGP were found to be comparable throughout the inflammation period studied, and were shown to increase to the same extent (see Results). So, it can be concluded that the change in fucosylation and in the type of branching of AGP are differently regulated.

We and others have supported evidence that changes in glycosylation of acute phase glycoproteins result from cytokine-induced variations in their biosynthesis in the liver (5–7, 10). It can be supposed, therefore, that the liver is also involved in the changes in glycosylation described in this study. The synthesis of SLeX-bearing glycans is inducible in the liver, since the occurrence has been described during liver cirrhosis, both on membrane-bound glycoproteins and on secreted AGP (15, 16, 40). Furthermore, the liver α1→3-fucosyltransferase is a likely candidate for the regulation of the enhancement of fucosylation, since the enzyme can transfer Fuc residues to α2→3-sialylated N-acetyllactosamine units of the glycans (41). Fucosylation of α2→6-sialylated N-acetyllactosamine units is prohibited by the structural requirements of the enzyme (41). However, it can be speculated that the acute phase–induced secretion of the α2→6-sialyltransferase (42–44) will lead to a decreased substitution of the glycans of AGP with α2→6-linked sialic acid, and consequently, will allow the resident α2→3-sialyltransferase and the α1→3-fucosyltransferase to introduce a SLeX type of structure on the corresponding N-acetyllactosamine units of the glycans. Such a type of regulation for the expression of SLeX has been suggested to occur in human myeloid cells during maturation (45). An acute phase–induced change in the substitution of AGP with α2→3-linked sialic acid residues is suggested from our results. A decrease, or at least a stabilization, in the expression of the α2→3-sialylated LeX structures on AGP is suggested from Fig. 3 at the fourth day of the laparotomy-induced inflammatory reaction, whereas the degree of fucosylation of AGP on the fourth day was higher.
than on the second day (Table 2). Studies are in progress to further substantiate these differences.

The inflammation-induced increase in SLeX-substituted glycans on AGP might represent a humoral mechanism provided by the liver for feedback inhibition of granulocyte extravasation into inflamed tissues (Fig. 5). Such a mechanism was proposed by Walz et al. (19) recently. They reported that increased fucosylation of AGP, by means of treatment with α1→3-fucosyltransferase, substantially increased its affinity for ELAM-1 or E-Selectin. E-Selectin mediates the primary interaction of inflamed endothelial cells with, e.g., granulocytes and memory T cells expressing the SLeX-containing glycans (19–23). Cytokines are involved in the expression of the E-Selectin on the endothelial cells, and, as is discussed above, are likely to be involved in the induction of the SLeX expression on AGP (Fig. 5). The possibility that an increase in the plasma level of SLeX-bearing AGP molecules will competitively inhibit the primary interaction of leukocytes with E-Selectin is in accordance with our finding that the changes in fucosylation reach a maximum to the end of the acute phase periods studied. The proposed inhibitory function of SLeX-expressing AGP can be extended to the cellular adhesion process mediated by P-Selectin (GMP140/PADGEM/CD62). SLeX-expressing molecules have also been reported to be ligands for this adhesion molecule, which mediates the adhesion between leukocytes and inflammation-induced endothelial cells or platelets (20, 21). SLeX-substituted AGP molecules, furthermore, are good candidates to serve as soluble binding proteins for Selectin molecules that have been shed from endothelial cells. It could be speculated that inflammation induces an expression of SLeX on a variety of acute phase glycoproteins, because acute phase-induced changes in glycosylation (Con A reactivity) are known to occur for all these molecules (2, 5, 7, 12). Our results, however, do not support a general phenomenon because no significant inflammation-induced changes in the AAL reactivity were detected for the acute phase glycoprotein PI. In future studies the above-mentioned hypotheses will be tested in in vitro cell adhesion assays using purified AGP isolated from patient sera before and after induction of the acute phase reaction.

The degree of sialylation and/or type of branching of the glycans of AGP have been reported to affect immunomodulatory properties of AGP, like lymphocyte proliferation (11, 14), the induction of IL-1-inhibiting activity in macrophages (13), and also the aggregation of platelets (46). The presence of fucose or of SLeX-substituted glycans has not been considered in these studies. To further understand the role(s) of AGP in the acute phase response, it seems necessary to reinvestigate the immunomodulatory properties of AGP as a function of the degree of substitution with SLeX.

We gratefully acknowledge Drs. E. M. J. Schutter (Department of Obstetrics and Gynecology, University Hospital, Vrije Universiteit) for the collection of some of the sera, the members of the Dutch Mycological Society for their effort in the collection of the fruiting bodies of Aleuria aurantia, Mr. G. M. Stroomberg for the isolation of AAL, and Mr. J. M. Verbeek for his assistance in the preparation of the illustrations. Prof. Dr. D. H. van den Eijnden (same institute) is acknowledged for his stimulating discussions and the critical reading of the manuscript.

Address correspondence to W. van Dijk, Department of Medical Chemistry, Faculty of Medicine, van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands.

Received for publication 28 July 1992 and in revised form 26 October 1992.

References

1. Niccollet, I., J.-P. Lebreton, M. Fontaine, and M. Hiron. 1981. Evidence for α1-acid glycoprotein populations of different pl values after concanavalin A affinity chromatography. Study of their evolution during inflammation in man. Biochim. Biophys. Acta. 668:235.
2. Koj, A., A. Dubin, H. Kasperczyck, J. Bereta, and A.H. Gordon. 1982. Changes in the blood level and affinity to concanavalin A of rat plasma glycoproteins during acute inflammation and hepatoma growth. Biochem. J. 206:545.
3. Mackiewicz, A., R. Marcinkowska-Pieta, S. Ballou, S. Mackiewicz, and I. Kushner. 1987. Microheterogeneity of α1-acid glycoprotein in the detection of intercurrent infection in systemic lupus erythematosus. Arthritis. Rheum. 30:185.
4. Bierhuizen, M., M. De Wit, M., C. Govers, W. Ferwerda, C. Koeleman, O. Pos, and W. Van Dijk. 1988. Glycosylation of three molecular forms of human α1-acid glycoprotein having different interactions with concanavalin A. Variations in the occurrence of di-, tri-, and tetraantenary glycans and the degree of sialylation. Eur. J. Biochem. 175:587.
5. Pos, O., M.E. Van der Stelt, G.-J. Wolkink, M.W.N. Nijsten, G.L. Van der Tempel, and W. Van Dijk. 1990. Changes in the serum concentration and the glycosylation of human α1-acid glycoprotein and α1-protease inhibitor in severely burned persons: relation to interleukin-6 levels. Clin. Exp. Immunol. 82:579.
6. Van Dijk, W., O. Pos, M.E. Van der Stelt, H.J. Moshage, S.-H. Yap, L. Dente, P. Baumann, and C.B. Eap. 1991. Inflammation-induced changes in expression and glycosylation of genetic variants of α1-acid glycoprotein. Studies with human sera, primary cultures of human hepatocytes and transgenic mice. Biochem. J. 276:343.
7. Mackiewicz, A., D. Schultz, and J. Mathison, M.K. Ganapathi,
and I. Kushner. 1989. Effect of cytokines on glycosylation of acute phase proteins in human hepatoma cell lines. Clin. Exp. Immunol. 75:70.

8. Castelli, J.V., M.J. Gomez-Lechon, M. David, R. Fabra, R. Triullenque, and P.C. Heinrich. 1990. Acute-phase response of human hepatocytes: Regulation of acute protein synthesis by interleukin-6. Hepatology. 12:1179.

9. Pos, O., H.J. Moshage, S.H. Yap, J.P.M. Schnieders, L.A. Aarden, J. Van Gool, W. Boer, A.M. Brugman, and W. Van Dijk. 1989. Effects of monocytic products, recombinant interleukin-1, and recombinant interleukin-6 on glycosylation of α1-acid glycoprotein: studies with primary human hepatocyte cultures and rats. Inflammation. 13:415.

10. Hiron, M., M. Daveau, and J.-P. Lefebre. 1991. Microheterogeneity of α1-acid glycoprotein and α2-HS in cultured rat and human hepatocytes and in cultures of human hepatoma cells: role of cytokines in the uncoupling of changes in secretion and in Con A reactivities of acute-phase glycoprotein. In Affinity Electrophoresis: Principles and Application. J. Breborowicz and A. Mackiewicz, editors. CRC Press, Inc., Boca Raton, FL. 163-179.

11. Bennett, M., and K. Schmid. 1980. Immunosuppression by human plasma α1-acid glycoprotein: importance of its carbohydrate moiety. Proc. Natl. Acad. Sci. USA. 77:6109.

12. Le Jeune, P.-J., B. Mallet, C. Farnarier, and S. Kaplanski. 1989. Changes in serum level and affinity for Concanavalin A of human α1-protease inhibitor in severe burn patients: relationship to natural killer activity. Biochem. Biophys. Acta. 990:122.

13. Bories, P.N., J. Feger, N. Benbernou, J. Agneray, and G. Durand. 1990. Prevalence of tri- and tetraantennary glycans and wild type N-glycans of human α1-acid glycoprotein in release of macrophage inhibitory activity. Inflammation. 14:315.

14. Pos, O., R.A.J. Oostendorp, M.E. Van der Stelt, R.J. Scheper, and W. Van Dijk. 1990. Con A-nonreactive human α1-acid glycoprotein (AGP) is more effective in modulation of lymphocyte proliferation than Con A-reactive AGP serum variants. Inflammation. 14:133.

15. Biou, D., D. Konan, J. Feger, J. Agneray, Y. Leroy, P. Cardon, B. Fournet, and G. Durand. 1987. Alterations in the carbohydrate moiety of α1-acid glycoprotein purified from human cirrhotic ascites fluid. Biochim. Biophys. Acta. 913:308.

16. J.M. Wierzuszek, B. Fournet, D. Konan, D. Biou, and G. Durand. 1988. 400-MHz 1H-NMR spectroscopy of fucosylated tetrasialy oligosaccharides isolated from normal and human plasma α1-acid glycoprotein. FEBS (Fed. Eur. Biochem. Soc.) Lett. 238:390.

17. Kannagi, R., Y. Fukushima, T. Tachikawa, A. Noda, S. Shim, K. Shigata, N. Hiraiwa, Y. Fukuda, T. Inamoto, S.-I. Hakomori, and H. Imura. 1984. Quantitative and qualitative characterization of human cancer-associated serum glycoproteins using fucosyl or fucosyl-fucosyl type 2 chain polylactosamine. Cancer Res. 46:2619.

18. Chia, D., P.I. Terasaki, N. Suyama, D. Perera, T. Hori, and D. Katz. 1985. Use of monoclonal antibodies to sialylated Lewis^a^ and sialylated Lewis^b^ for serological tests of cancer. Cancer Res. 45:435.

19. Wálcz, G., A. Arufio, W. Kolanus, M. Bevilacqua, and B. Seed. 1990. Recognition by ELAM-1 of the sialyl-Le^a^ determinant on myeloid and tumor cells. Science (Wash. DC). 250:1132.

20. Zhou, Q., K.L. Moore, D.F. Smith, A. Varli, R.P. McEver, and R.D. Cummings. 1991. The selectin GMP-140 binds to sialylated, fucosylated lactosaminoglycans on both myeloid and nonmyeloid cells. J. Cell. Biol. 115:557.

21. Lasky, L.A. 1991. Lectin cell adhesion molecules (LEC-CAMs): a new family of cell adhesion proteins involved in inflammation. J. Cell. Biochem. 45:139.

22. Springer, T.A., and L.A. Lasky. 1991. Sticky sugars for selections. Nature (Lond.). 349:196.

23. Shimizu, Y., S. Shaw, N. Graber, T.V. Gopal, K.J. Horgan, G.A. van Seventer, and W. Newman. 1991. Activation-independent binding of human memory T cells to adhesion molecule ELAM-1. Nature (Lond.). 349:799.

24. Debray, H., and J. Montereuil. 1989. Aleuria aurantia agglutinin. A new isolation procedure and further study of its specificity towards various glycoepitides and oligosaccharides. Carbohydr. Res. 185:15.

25. Diabaté, S., R. Geyer, and S. Stirm. 1984. Structure of the major oligosaccharides in the fusion glycoprotein of Newcastle disease virus. Eur. J. Biochem. 139:329.

26. Bierhuizen, M.F.A., Edzes, H.T., Schiphorst, W.E.C.M., Van den Eijnden, D.H., and Van Dijk, W. 1988. Effect of α2→6-linked sialic acid and α1→3-linked fucose on the interaction of N-linked glycoepitides and related oligosaccharides with immobilized Phaseolus vulgaris leukoagglutinating lectin (LPHA). Glycoconj. J. 5:85.

27. Bog-Hansen, T.C. 1973. Crossed immunoelectrophoresis: an analytical method to predict the result of affinity chromatography. Anal. Biochem. 56:480.

28. Mancini, G., J.-P. Voerman, A.O. Carbonara, and J.F Heremans. 1964. A single radial-diffusion method for the immunological quantitation of proteins. Probes. Biol. Fluids Proc. Cil. 11:370.

29. Van Dijk, W., and M.E. Van der Stelt. 1991. A rapid isolation procedure of differently glycosylated forms of acute-phase glycoproteins by preparative crossed affinity electrophoresis. In Affinity Electrophoresis: Principles and Application. J. Breborowicz and A. Mackiewicz, editors. CRC Press Inc., Boca Raton, FL. 81-86.

30. Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.). 227:680.

31. Fukushima, K., M. Hirota, P.I. Terasaki, A. Wakisaka, H. Togashi, D. Chia, N. Suyama, Y. Fukushima, E. Nudelman, and S.-I. Hakomori. 1984. Characterization of sialosylated Lewis^a^ as a new tumor-associated antigen. Cancer Res. 44:5279.

32. Debray, H., and J. Montereuil. 1991. Specificity of lectins toward oligosaccharide sequences belonging to N- and O-glycosylproteins. In Affinity Electrophoresis: Principles and Application. J. Breborowicz and A. Mackiewicz, editors. CRC Press Inc., Boca Raton, FL. 23-57.

33. Chandrasekaran, E.V., M. Davila, D. Nixon, and J. Mendicino. 1984. Structure of the oligosaccharide chains of two forms of α1-acid glycoprotein from liver metastasis of lung colon and breast tumors. Cancer Res. 44:1557.

34. Fournet, B., J. Montereuil, G. Strecker, L. Dorland, J. Haverkamp, J.F. Vliegenthart, J.P. Binette, and K. Schmid. 1978. Determination of the primary structures of 16 asialo glycopeptides and related oligosaccharides with immobilized Phaseolus vulgaris leukoagglutinating lectin (LPHA). Glycoconj. J. 5:85.
36. Yoshima, H., A. Matsumoto, T. Mizuochi, T. Kawasaki, and A. Kobata. 1981. Comparative study of the carbohydrate moieties of rat and human plasma α1-acid glycoproteins. J. Biol. Chem. 256:8467.
37. Carbon, P., J.P. Parente, Y. Leroy, J. Montreuil, and B. Fournet. 1986. Separation of sialyl-oligosaccharides by high-performance liquid chromatography. Application to the analysis of mono-, di-, tri-, and tetrasialyl-oligosaccharides obtained by hydrazinolysis of α1-acid glycoprotein. J. Chromatogr. 356:135.
38. Thompson, S., D. Guthrie, and G.A. Turner. 1988. Fucosylated forms of alpha-1-antitrypsin that predict unresponsiveness to chemotherapy in ovarian cancer. Br. J. Cancer. 58:589.
39. Thompson, S., B.M.J. Cantwell, C. Cornell, and G.A. Turner. 1991. Abnormally-fucosylated haptoglobin: a cancer marker for tumour burden but not gross liver metastasis. Br. J. Cancer. 64:386.
40. Okada, Y., T. Shimoe, M. Muguruma, R. Usumoto, T. Tsuji, K. Jinno, S. Morikawa, S. Shin, and S.-I. Hakomori. 1988. Hepatocellular expression of a novel glycoprotein with sialylated difucosyl Le^ activity in the active inflammatory lesions of chronic liver disease. Am. J. Pathol. 130:384.
41. Macher, B.A., E.H. Holmes, S.J. Swiedler, C.L.M. Stults, and C.A. Srnka. 1991. Human α1→3 fucosyltransferases. Glycobiology. 1:577.
42. Kaplan, H.A., B.M.R.N.J. Woloski, M. Hellman, and J.C. Jamieson. 1983. Studies on the effect of inflammation on rat liver and serum sialyltransferase. Evidence that inflammation causes release of Gal1→4GlcNAc α2→6-sialyl-transferase from liver. J. Biol. Chem. 258:11505.
43. Van Dijk, W., W. Boers, M. Sala, A.H.M. Lasthuis, and S. Mookerjea. 1986. Activity and secretion of sialyltransferase in primary monolayer cultures of rat hepatocytes cultured with and without dexamethasone. Biochem. Cell Biol. 64:79.
44. Woloski, B.M., G.M. Fuller, J.C. Jamieson, and E. Gospodarek. 1986. Studies on the effect of the hepatocyte-stimulating factor on galactose-β-4-N-acetylglucosamine α2→6-sialyltransferase in cultured hepatocytes. Biochim. Biophys. Acta. 885:185.
45. Skacel, P.O., A.J. Edwards, C.T. Harrison, and W.M. Watkins. 1991. Enzymic control of the expression of the X-determinant (CD15) in human myeloid cells during maturation: the regulatory role of 6′-sialyltransferase. Blood. 78:1452.
46. Costello, M., B.A. Fiedel, and H. Gewurz. 1979. Inhibition of platelet aggregation by native and desialised α1-acid glycoprotein. Nature (Lond.). 281:677.